These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 29616706)

  • 41. Cyclandelate in the treatment of patients with mild to moderate primary degenerative dementia of the Alzheimer type or vascular dementia: experience from a placebo controlled multi-center study.
    Weyer G; Eul A; Milde K; Wierich W; Herrmann WM
    Pharmacopsychiatry; 2000 May; 33(3):89-97. PubMed ID: 10855459
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A randomized controlled study on effects of ibuprofen on cognitive progression of Alzheimer's disease.
    Pasqualetti P; Bonomini C; Dal Forno G; Paulon L; Sinforiani E; Marra C; Zanetti O; Rossini PM
    Aging Clin Exp Res; 2009 Apr; 21(2):102-10. PubMed ID: 19448381
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer's Disease.
    Egan MF; Kost J; Tariot PN; Aisen PS; Cummings JL; Vellas B; Sur C; Mukai Y; Voss T; Furtek C; Mahoney E; Harper Mozley L; Vandenberghe R; Mo Y; Michelson D
    N Engl J Med; 2018 May; 378(18):1691-1703. PubMed ID: 29719179
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The validity and reliability of the Turkish version of Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) in patients with mild and moderate Alzheimer's disease and normal subjects.
    Mavioglu H; Gedizlioglu M; Akyel S; Aslaner T; Eser E
    Int J Geriatr Psychiatry; 2006 Mar; 21(3):259-65. PubMed ID: 16477580
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Targeting amyloid β in Alzheimer's disease: Meta-analysis of low-dose solanezumab in Alzheimer's disease with mild dementia studies.
    Holdridge KC; Yaari R; Hoban DB; Andersen S; Sims JR
    Alzheimers Dement; 2023 Oct; 19(10):4619-4628. PubMed ID: 36946603
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy of higher-dose 13.3 mg/24 h (15 cm2) rivastigmine patch on the Alzheimer's Disease Assessment Scale-cognitive subscale: domain and individual item analysis.
    Alva G; Isaacson R; Sadowsky C; Grossberg G; Meng X; Somogyi M
    Int J Geriatr Psychiatry; 2014 Sep; 29(9):920-7. PubMed ID: 24549933
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Diagnostic value and functional correlations of the ADAS-Cog scale in Alzheimer's disease: data on NORMACODEM project].
    Monllau A; Pena-Casanova J; Blesa R; Aguilar M; Bohm P; Sol JM; Hernandez G
    Neurologia; 2007 Oct; 22(8):493-501. PubMed ID: 17602338
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Suitability of the Clinical Dementia Rating-Sum of Boxes as a single primary endpoint for Alzheimer's disease trials.
    Coley N; Andrieu S; Jaros M; Weiner M; Cedarbaum J; Vellas B
    Alzheimers Dement; 2011 Nov; 7(6):602-610.e2. PubMed ID: 21745761
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy and Safety of ABT-126 in Subjects with Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors: A Randomized, Double-Blind, Placebo-Controlled Study.
    Florian H; Meier A; Gauthier S; Lipschitz S; Lin Y; Tang Q; Othman AA; Robieson WZ; Gault LM
    J Alzheimers Dis; 2016; 51(4):1237-47. PubMed ID: 26967214
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Donepezil for vascular cognitive impairment.
    Malouf R; Birks J
    Cochrane Database Syst Rev; 2004; (1):CD004395. PubMed ID: 14974068
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Randomized, double-blind, parallel-group, 48-week study for efficacy and safety of a higher-dose rivastigmine patch (15 vs. 10 cm²) in Alzheimer's disease.
    Cummings J; Froelich L; Black SE; Bakchine S; Bellelli G; Molinuevo JL; Kressig RW; Downs P; Caputo A; Strohmaier C
    Dement Geriatr Cogn Disord; 2012; 33(5):341-53. PubMed ID: 22796905
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Galantamine for Alzheimer's disease.
    Olin J; Schneider L
    Cochrane Database Syst Rev; 2001; (1):CD001747. PubMed ID: 11279727
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Bapineuzumab for mild to moderate Alzheimer's disease in two global, randomized, phase 3 trials.
    Vandenberghe R; Rinne JO; Boada M; Katayama S; Scheltens P; Vellas B; Tuchman M; Gass A; Fiebach JB; Hill D; Lobello K; Li D; McRae T; Lucas P; Evans I; Booth K; Luscan G; Wyman BT; Hua L; Yang L; Brashear HR; Black RS;
    Alzheimers Res Ther; 2016 May; 8(1):18. PubMed ID: 27176461
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Quantification of disease progression and dropout for Alzheimer's disease.
    William-Faltaos D; Chen Y; Wang Y; Gobburu J; Zhu H
    Int J Clin Pharmacol Ther; 2013 Feb; 51(2):120-31. PubMed ID: 23211395
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The Alzheimer's Disease Assessment Scale: patterns and predictors of baseline cognitive performance in multicenter Alzheimer's disease trials.
    Doraiswamy PM; Bieber F; Kaiser L; Krishnan KR; Reuning-Scherer J; Gulanski B
    Neurology; 1997 Jun; 48(6):1511-7. PubMed ID: 9191757
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Psychometric Evaluation of the Neuropsychological Test Battery in Individuals with Normal Cognition, Mild Cognitive Impairment, or Mild to Moderate Alzheimer's Disease: Results from a Longitudinal Study.
    Harrison JE; Rentz DM; Brashear HR; Arrighi HM; Ropacki MT; Liu E
    J Prev Alzheimers Dis; 2018; 5(4):236-244. PubMed ID: 30298182
    [TBL] [Abstract][Full Text] [Related]  

  • 57. An Arabic Version of the Cognitive Subscale of the Alzheimer's Disease Assessment Scale (ADAS-Cog): Reliability, Validity, and Normative Data.
    Ben Jemaa S; Attia Romdhane N; Bahri-Mrabet A; Jendli A; Le Gall D; Bellaj T
    J Alzheimers Dis; 2017; 60(1):11-21. PubMed ID: 28505978
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Two-year treatment of Alzheimer's disease with eptastigmine. The Eptastigmine Study Group.
    Imbimbo BP; Verdelli G; Martelli P; Marchesini D
    Dement Geriatr Cogn Disord; 1999; 10(2):139-47. PubMed ID: 10026388
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies.
    Mecocci P; Bladström A; Stender K
    Int J Geriatr Psychiatry; 2009 May; 24(5):532-8. PubMed ID: 19274640
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Circulating cholesterol levels, apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin treatment in Alzheimer's disease: results of the Alzheimer's Disease Cholesterol-Lowering Treatment (ADCLT) trial.
    Sparks DL; Connor DJ; Sabbagh MN; Petersen RB; Lopez J; Browne P
    Acta Neurol Scand Suppl; 2006; 185():3-7. PubMed ID: 16866904
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.